文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌诊断后戒烟治疗项目的生存结局

Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2026-06-03

该前瞻性队列纳入169例膀胱癌患者,接受个体化烟草治疗并在3、6、9个月评估戒烟状态。中位随访5.7年,3、6、9个月戒烟均独立关联更优总生存(校正风险比分别为0.56、0.45、0.51),癌特异生存和无复发生存亦改善。结论支持对所有膀胱癌患者强烈鼓励戒烟。

要点

  • 膀胱癌诊断后3、6、9个月戒烟率分别为43%、44%、38%。
  • 3、6、9个月戒烟均独立关联更优总生存,校正风险比0.56、0.45、0.51。
  • 任一随访点戒烟均与癌特异生存和无复发生存显著改善相关。

核心结论

  • 膀胱癌诊断后戒烟与改善生存相关,应强烈鼓励所有膀胱癌患者戒烟。

研究设计与样本

  • 来自烟草研究与治疗项目(TRTP)的169例2006至2022年诊断的尿路上皮膀胱癌患者子集,采用个体化烟草治疗策略并在3、6、9个月收集自我报告的戒烟信息。

主要发现

  • 3、6、9个月戒烟率分别为43%、44%、38%。
  • 中位随访5.7年,3、6、9个月戒烟均独立关联更优总生存,校正风险比分别为0.56、0.45、0.51。
  • 任一随访点戒烟均与癌特异生存和无复发生存显著改善相关。

临床怎么用

  • 对膀胱癌患者应强烈鼓励戒烟,并在诊断后尽早提供个体化烟草治疗。

局限性

  • 队列以白人男性为主,可能限制对更多样化人群的推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Smoking is the strongest modifiable risk factor for the development of bladder cancer. The benefits of smoking abstinence following a bladder cancer diagnosis are uncertain. Our objective was to determine the association of smoking abstinence with survival following the diagnosis of bladder cancer compared with continued smoking. METHODS: A subset of 169 patients from the Tobacco Research and Treatment Program (TRTP) was identified following a diagnosis of urothelial bladder cancer between 2006 and 2022. Individualized tobacco treatment strategies were employed, and self-reported abstinence information was collected at 3, 6, and 9 mo following consultation. The primary outcome was overall survival (OS), analyzed according to smoking abstinence status. Secondary outcomes included cancer-specific survival (CSS), recurrence-free survival (RFS), and metastasis-free survival (MFS). KEY FINDINGS AND LIMITATIONS: Smoking abstinence rates were 43%, 44%, and 38% at the 3-, 6-, and 9-mo assessments, respectively. After a median follow-up of 5.7 yr, abstinence at 3, 6, and 9 mo was independently associated with superior OS (adjusted hazard ratios were 0.56, 0.45, and 0.51, respectively). CSS and RFS were likewise significantly improved whenever abstinence was achieved at any follow-up point. Limitations include the predominantly White, male cohort, which may limit generalizability to more diverse populations. CONCLUSIONS AND CLINICAL IMPLICATIONS: Smoking abstinence following the diagnosis of bladder cancer was associated with improved survival in our prospective cohort. Smoking cessation should be strongly encouraged in all patients with bladder cancer. IRB protocol number: DR07-0884 (Institutional Review Board at The University of Texas MD Anderson Cancer Center).

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. MacDonald LP, Kypriotakis G, Karam-Hage M, et al. Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder Cancer. Eur Urol Oncol. 2026. PMID: 42236415. doi:10.1016/j.euo.2026.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。